STOCK TITAN
  1. Home
  2. Sec-filings
  3. ABT
  4. [Form 3] ABBOTT LABORATORIES Initial Statement of Beneficial Ownership

Kevin Conroy (ABBOTT LABORATORIES: ABT) reports 131,451-share Form 3 holding

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

ABBOTT LABORATORIES director Kevin T. Conroy filed an initial Form 3 reporting his equity stake following Abbott’s acquisition of Exact Sciences. He reports direct beneficial ownership of 131,451 common shares without par value. This position primarily reflects restricted stock units that accelerated upon Exact’s change in control at the merger’s effective time.

Under the merger completed on March 23, 2026, each share of Exact common stock was converted into the right to receive $105.00 in cash, without interest, subject to withholding taxes. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock unit awards based on the merger consideration and the 10‑day average Abbott share price. The reported RSU award fully accelerated at separation; one quarter was settled immediately, and the remaining three quarters will be settled in shares six months and one day after the effective time, with an option to have shares withheld for taxes.

Positive

  • None.

Negative

  • None.
Insider Conroy Kevin T
Role null
Type Security Shares Price Value
holding Common shares without par value -- -- --
Holdings After Transaction: Common shares without par value — 131,451 shares (Direct, null)
Footnotes (1)
  1. On March 23, 2026, Abbott Laboratories ("Abbott") acquired Exact Sciences Corporation ("Exact") pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the "Merger Agreement"), by and among Abbott, Exact and Badger Merger Sub I, Inc. ("Merger Sub"). Pursuant to the terms of, and subject to the conditions contained in, the Merger Agreement, Merger Sub merged with and into Exact, with Exact surviving as a direct, wholly owned subsidiary of Abbott (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.01 per share, of Exact ("Exact common stock") issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was automatically converted into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes (the "Merger Consideration"). Further, each restricted stock unit award granted under an Exact stock plan (each, an "RSU") on or after November 19, 2025, other than RSU awards granted to Exact's non-employee directors, was assumed by Abbott at the Effective Time as an Abbott restricted stock unit award on substantially the same terms and conditions as were applicable to the corresponding RSU award (including with respect to double-trigger vesting protections), with the number of Abbott common shares underlying such Abbott restricted stock unit award determined based on the Merger Consideration divided by the average closing price of an Abbott common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time. These shares represent an RSU award that fully accelerated and became payable upon the reporting person's separation from service upon the Exact change in control at the Effective Time. One quarter of the award was settled immediately at the Effective Time. The remaining three quarters of the award will be settled in shares six months and one day after the Effective Time. The award includes the right to have shares withheld for tax purposes.
Reported Abbott common shares 131,451 shares Total shares beneficially owned following transaction
Exact merger cash consideration $105.00 per share Cash paid for each Exact common share at merger
Merger effective date March 23, 2026 Date Abbott’s acquisition of Exact Sciences became effective
RSU settlement timing Six months and one day Delay before remaining three quarters of RSU award settle in shares
restricted stock unit financial
"each restricted stock unit award granted under an Exact stock plan (each, an "RSU")"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Merger Consideration financial
"was automatically converted into the right to receive $105.00 in cash ... (the "Merger Consideration")"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
change in control financial
"upon the reporting person's separation from service upon the Exact change in control at the Effective Time"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Effective Time regulatory
"At the effective time of the Merger (the "Effective Time"), each share of common stock"
double-trigger vesting protections financial
"on substantially the same terms and conditions ... (including with respect to double-trigger vesting protections)"
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Conroy Kevin T
(Last)(First)(Middle)
100 ABBOTT PARK ROAD
(Street)
ABBOTT PARK ILLINOIS 60064
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
04/24/2026		3. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares without par value131,451(1)(2)(3)D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On March 23, 2026, Abbott Laboratories ("Abbott") acquired Exact Sciences Corporation ("Exact") pursuant to the Agreement and Plan of Merger, dated as of November 19, 2025 (the "Merger Agreement"), by and among Abbott, Exact and Badger Merger Sub I, Inc. ("Merger Sub"). Pursuant to the terms of, and subject to the conditions contained in, the Merger Agreement, Merger Sub merged with and into Exact, with Exact surviving as a direct, wholly owned subsidiary of Abbott (the "Merger"). At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.01 per share, of Exact ("Exact common stock") issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was automatically converted into the right to receive $105.00 in cash, without interest, less any applicable withholding taxes (the "Merger Consideration").
2. Further, each restricted stock unit award granted under an Exact stock plan (each, an "RSU") on or after November 19, 2025, other than RSU awards granted to Exact's non-employee directors, was assumed by Abbott at the Effective Time as an Abbott restricted stock unit award on substantially the same terms and conditions as were applicable to the corresponding RSU award (including with respect to double-trigger vesting protections), with the number of Abbott common shares underlying such Abbott restricted stock unit award determined based on the Merger Consideration divided by the average closing price of an Abbott common share for the 10 consecutive trading days ending on and including the trading day immediately preceding the Effective Time.
3. These shares represent an RSU award that fully accelerated and became payable upon the reporting person's separation from service upon the Exact change in control at the Effective Time. One quarter of the award was settled immediately at the Effective Time. The remaining three quarters of the award will be settled in shares six months and one day after the Effective Time. The award includes the right to have shares withheld for tax purposes.
/s/ Kevin T. Conroy by Jessica H. Paik, Attorney-in-Fact04/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Kevin T. Conroy’s Form 3 filing for ABBOTT LABORATORIES (ABT) show?

The Form 3 shows Kevin T. Conroy’s initial beneficial ownership of 131,451 Abbott common shares. This stake arises from restricted stock units tied to Abbott’s acquisition of Exact Sciences and their acceleration upon the change in control at the merger’s effective time.

How were Exact Sciences shareholders compensated in the Abbott acquisition of Exact?

Each share of Exact Sciences common stock was automatically converted into the right to receive $105.00 in cash. This cash consideration was paid without interest and was reduced by any applicable withholding taxes, as specified in the merger agreement among Abbott, Exact, and the merger subsidiary.

How were Exact Sciences restricted stock units treated in the Abbott (ABT) merger?

Restricted stock unit awards granted under an Exact stock plan on or after November 19, 2025, other than director RSUs, were assumed by Abbott. They became Abbott RSU awards on substantially the same terms, with share counts determined by the merger consideration divided by Abbott’s 10‑day average closing share price.

What happens to Kevin T. Conroy’s RSU award after the Exact change in control?

Conroy’s RSU award fully accelerated upon his separation at the Exact change in control. One quarter of the award was settled immediately at the effective time, while the remaining three quarters will be settled in Abbott shares six months and one day later, with shares available for tax withholding.

Does Kevin T. Conroy’s Form 3 reflect any recent buy or sell transactions in Abbott stock?

The Form 3 is an initial ownership report and does not show explicit buy or sell transactions. It records 131,451 Abbott common shares held directly, primarily stemming from accelerated and converted RSU awards related to Abbott’s completed acquisition of Exact Sciences.